[go: up one dir, main page]

WO2025181366A1 - Formulations topiques d'inhibiteurs de pi3k/mtor doubles - Google Patents

Formulations topiques d'inhibiteurs de pi3k/mtor doubles

Info

Publication number
WO2025181366A1
WO2025181366A1 PCT/EP2025/055580 EP2025055580W WO2025181366A1 WO 2025181366 A1 WO2025181366 A1 WO 2025181366A1 EP 2025055580 W EP2025055580 W EP 2025055580W WO 2025181366 A1 WO2025181366 A1 WO 2025181366A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight percent
compound
pharmaceutical composition
composition comprises
topical pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/055580
Other languages
English (en)
Inventor
Vladimir Cmiljanovic
Natasa Cmiljanovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torqur Ag
Original Assignee
Torqur Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torqur Ag filed Critical Torqur Ag
Publication of WO2025181366A1 publication Critical patent/WO2025181366A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • Mammalian target of rapamycin is a large serine/threonine specific protein kinase which can combine with protein binding partners to form one of two functionally distinct mTOR complexes, mTORCl and mTORC2, which regulate different cellular processes.
  • mTOR can be inhibited by either inhibition of upstream kinases such as PI3K and/or AKT or by directly inhibiting the mTOR kinase either allosterically (e.g., by rapamycin) or by ATP site directed inhibitors (Saxton RA, Sabatini DM Cell, (2017) 168:960- 976).
  • PI3K/mTOR signaling plays a role in the development of skin disease.
  • NMSC non-melanoma skin cancer
  • AK actinic keratosis
  • cSCC cutaneous squamous cell carcinoma
  • Bimiralisib is a dual PI3K/mTOR inhibitor that has shown activity in mouse models of skin disorders such as AK and cSCC (WO 2017/198347).
  • WO 2019/087158 teaches a formulation comprising an oxazolidin-2-one-pyrimidine compound.
  • attempts to prepare topical galenic compositions comprising this compound faced difficulties because it showed limited solubility, and solubility is an important factor influencing drug loading.
  • the compound was found to be unstable in the presence of solvents such as PEG400 (WO 2019/087158). Accordingly, the topical pharmaceutical compositions taught in WO 2019/087158 only contained up to 0.3% of active compound, and only provided a skin concentration of 1.12 pg/g even after once daily application for two weeks in a minipig study.
  • the value of 1.12 pg/g was obtained without prior removal of the stratum comeum, and thus represents the drug concentration in the skin including the concentration in the stratum comeum, which as noted above can act as a reservoir to sequester active agents away from, e.g., the epidermis and dermis. Accordingly, there is a need for clinically acceptable topical formulations of PI3K and/or dual PI3K/mTOR inhibitors that can penetrate through the stratum comeum to the epidermis and dermis of human skin.
  • the present invention relates to topical pharmaceutical compositions comprising a compound of Formula (I).
  • inventive topical pharmaceutical compositions comprise mixtures of solvents and excipients (e.g., polyethylene glycol and diethylene glycol monoethyl ether) that are surprisingly able to dissolve increased amounts of compounds of Formula (I) in a synergistic manner. Accordingly, greater amounts of compounds of Formula (I) were able to be dissolved in the inventive topical pharmaceutical compositions than would have been predicted based on the solubility of the compounds of Formula (I) in the individual solvents and excipients alone.
  • solvents and excipients e.g., polyethylene glycol and diethylene glycol monoethyl ether
  • the resulting increased solubility of the compounds of Formula (I) in the inventive topical pharmaceutical concentrations helped contribute to greater skin penetration of the compounds of Formula (I) in human skin and pig skin models.
  • the increased penetration of compounds of Formula (I) through the stratum comeum and into the epidermis and dermis is expected to enable more favorable clinical outcomes in patients with skin lesions including AK and cSCC.
  • the compounds of Formula (I) were found to be stable under most accelerated degradation conditions.
  • the compounds of Formula (I) were also found to be stable under accelerated degradation conditions when formulated in the inventive topical pharmaceutical compositions disclosed herein.
  • compositions tested were not able to dissolve increased amounts of compounds of Formula (I) in a synergistic manner.
  • a composition comprising less than 50% of a polyethylene glycol (e.g., less than 45%, less than 30% polyethylene glycol) was able to dissolve less of a compound of Formula (I) than would have been expected based on the solubility of the compound of Formula (I) in the individual solvents and excipients alone.
  • the present invention provides a topical pharmaceutical composition comprising: at least 0.1 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent polyalkylene glycol, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent diethylene glycol monoethyl ether, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 0.3 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent polyalkylene glycol, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent diethylene glycol monoethyl ether, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 0.5 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl. or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent polyalkylene glycol, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent diethylene glycol monoethyl ether, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 0.9 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 45 weight percent polyalkylene glycol; and at least 15 weight percent di ethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 1.5 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 45 weight percent polyalkylene glycol; and at least 15 weight percent di ethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 1.9 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 45 weight percent polyalkylene glycol; and at least 15 weight percent di ethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition as described herein for use in a method of treating a skin lesion or skin disorder in a subject, preferably wherein said skin lesion or skin disorder is actinic keratosis (AK).
  • AK actinic keratosis
  • FIG 1 is a schematic of the static Franz cell used to assess the release profile of Compound 1 across a synthetic cellulose membrane for the ten experimental formulations tested in Example 3.
  • the top-to-bottom order of the formulation labels on the right-hand legend is the same as the top-to-bottom order of the cumulative amount of Compound 1 released after (2.65) 2 hours, i.e., the highest amount of Compound 1 was released by NA03, and the lowest amount was released by AG18.
  • FIG 3 is a schematic of the diffusion cell used to test the ex vivo skin penetration of selected formulations as described in Example 4.
  • FIG 4 is a plot of the amount of Compound 1 recovered from human skin (epidermis and dermis) as set forth in Example 4.
  • FIG 5 is a schematic showing where the tested formulations were applied on the back of a domestic pig as described in Example 5.
  • FIG 7 is a bar graph showing the total amount of Compound 1 isolated from domestic pig skin biopsies after in vivo administration of 11 tested formulations, integrated over the timepoints 6, 9, and 12 hours.
  • FIG 8 is a schematic showing where the tested formulations were applied on the back of a domestic pig as described in Example 6.
  • FIG 9 shows the averaged (mean ⁇ SEM) concentrations of Compound 1 in the skin of a domestic pig after application of all formulations, and integrated over all time points (6h, 9h, 12 h).
  • FIG 10 is a schematic of the design of the clinical trial protocol described in Example 7.
  • the present invention relates to topical pharmaceutical compositions comprising a compound of Formula (I).
  • inventive topical pharmaceutical compositions comprise mixtures of solvents and excipients (e.g., at least 45 weight percent polyalkylene glycol and at least 15 weight percent di ethylene glycol monoethyl ether) that are able to dissolve increased amounts of compounds of Formula (I) in a synergistic manner.
  • solvents and excipients e.g., at least 45 weight percent polyalkylene glycol and at least 15 weight percent di ethylene glycol monoethyl ether
  • the formulation NA03 was expected to dissolve 1.85 g Compound 1 per 100 g of total formulation based on the solubility of Compound 1 in the individual solvents and excipients comprising NA03. Surprisingly, NA03 was capable of dissolving up to 7.88 g Compound 1. This represents a synergistic solubility factor of 4.26.
  • the formulation AG20 was expected to dissolve 1.89 g Compound 1 per 100 g of total formulation based on the solubility of Compound 1 in the individual solvents and excipients comprising AG20. Surprisingly, AG20 was capable of dissolving up to 4 g compound 1. This represents a synergistic solubility factor of 2.11.
  • the formulation CR01 which comprises less than 45% (wt/wt) PEG 400, was expected to dissolve 1.7 g Compound 1 per 100 g of total formulation based on the solubility of Compound 1 in the individual solvents and excipients comprising CR01.
  • CR01 was only capable of dissolving up to 1.375 g Compound 1 per 100 g of total formulation. This represents a solubility factor of 0.8.
  • the resulting increased solubility of the compounds of Formula (I) in the inventive topical pharmaceutical concentrations helped contribute to greater skin penetration of the compounds of Formula (I) through the stratum comeum and into the epidermis and dermis in human skin and pig skin models.
  • the non-aqueous gel (NA03) showed the fastest release rate of Compound 1 through a synthetic membrane, which represented an approximately 2- to 5 -fold increase over all other tested formulations.
  • the formulations AG20, EG01, and AG21 all had statistically the same release rates and were the next-highest ranked formulations for release rate after NA03.
  • the formulation NA03 delivered 1.7 to 17-fold more Compound 1 to the epidermis compared with all other tested formulations.
  • Formulation NA03 was also the third- highest ranked formulation for dermal delivery.
  • Formulations AG20 and AG21 delivered the highest amount of Compound 1 to both the dermis and epidermis of the tested aqueous gels.
  • formulations NA03 and AG20 gave the highest concentrations of Compound 1 in the skin of the experimental compounds tested. As shown in FIG 7, when integrated over the three timepoints tested (i.e., 6 h, 9 h and 12 h), the formulations NA03 and AG20 delivered an amount of Compound 1 above the IC90 for phosphoS6 inhibition after a single application.
  • the compounds of Formula (I) were found to be stable under forced degradation conditions designed to accelerate degradation. As shown in Table 4, compound 1 was stable under all conditions tested except for 0.1N HC1 at 90 °C.
  • the term “about” as used herein shall have the meaning of +/- 10%.
  • about 50% shall mean 45% to 55%.
  • the term “about” as used herein shall have the meaning of +/- 5%.
  • about 50% shall mean 47.5% to 52.5%.
  • said term “about” refers to any value of a range of and between - 10% and +10% of the value it refers to.
  • said term “about” refers to any value of a range of and between - 8% and +8% of the value it refers to.
  • said term “about” refers to any value of and between a range of - 7% and +7% of the value it refers to.
  • said term “about” refers to any value of and between a range of - 5% to +5% of the value it refers to. In a preferred embodiment, said term “about” refers to any value of and between a range of - 4% and +4% of the value it refers to. In a preferred embodiment, said term “about” refers to any value of and between a range of - 3% and +3% of the value it refers to. In a preferred embodiment, said term “about” refers to any value of and between a range of - 2% and +2% of the value it refers to. In a preferred embodiment, said term “about” refers to any value of and between a range of - 1% and +1% of the value it refers to. In some embodiments, the term “about” refers to the exact value stated.
  • between value X and value Y shall refer to include the value X and the value Y and any value in between.
  • the phrase “between 0.01 mg and 50 mg” refers to 0.01 mg and 50 mg and any value in between.
  • the phrase “from value X to value Y”, as used herein, shall refer to include the value X and the value Y and any value in between.
  • the phrase “between 65% and 75%” refers to 65% and 75% and any value in between.
  • % (w/w) refers to (mass of the component / total mass of the composition) x 100.
  • 70 wt% PEG400 is 70 g PEG400 per 100 g of the composition.
  • topically and “topical” refers to application of the composition of the present invention to the surface of the skin of a subject, preferably of a human, and thus, the term “topical administration”, as used herein, refers to administration to the skin of a subject, preferably of a human, preferably for the treatment of a skin lesion.
  • topical composition refers to a composition that is suitable for topical administration and may be applied to skin of a subject, preferably of a human.
  • treatment refers to prophylaxis and/or therapy.
  • treatment refers to a therapeutic treatment.
  • treatment refers to a prophylactic treatment.
  • beneficial or desired clinical results of said treatment include, but are not limited to, alleviation of symptoms, diminishment of extent of disease or disorder, stabilized (z.e., not worsening) state of disease or disorder, delay or slowing of disease or disorder progression, amelioration or palliation of the disease or disorder state.
  • the term “effective amount” refers to an amount necessary or sufficient to realize a desired biologic effect.
  • the term “effective amount” refers to an amount of a compound of Formula (I) of the present invention that (i) treats or prevents the particular disease or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or disorder, described herein.
  • An effective amount of the inventive compound of Formula (I), or said topical composition or said pharmaceutical composition would be the amount that achieves this selected result, and such an amount could be determined as a matter of routine by a person skilled in the art.
  • the term “effective amount”, as used herein, refers to an amount necessary or sufficient to inhibit PI3K and/or mTOR (e.g., to inhibit 50%, 90%, or more of the activity of PI3K and/or mTOR).
  • the effective amount can vary depending on the particular composition being applied and the size of the subject.
  • One of ordinary skill in the art can empirically determine the effective amount of a particular the inventive compound of Formula (I), or said topical composition or said pharmaceutical composition of the present invention without necessitating undue experimentation.
  • mammal includes, but is not limited to, humans, mice, rats, guinea pigs, monkeys, dogs, cats, horses, cows, pigs, and sheep.
  • AG stands for aqueous gel.
  • Formulations described herein starting with the letters AG are understood as aqueous gels.
  • An aqueous gel as used herein is understood as a topical pharmaceutical composition in the form of a gel and that comprises at least 5% water (wt/wt), preferably at least 9% water (wt/wt).
  • EG stands for emulsified gel. Formulations described herein starting with the letters EG are understood as emulsified gels.
  • NA non-aqueous gel
  • Formulations described herein starting with the letters NA are understood as non-aqueous gels.
  • a non-aqueous gel as used herein is understood as a topical pharmaceutical composition in the form of a gel that is substantially anhydrous.
  • a “substantially anhydrous” topical pharmaceutical composition can comprise trace amounts of water (e.g., below about 1 % wt/wt, preferably below about 0.1% wt/wt). Said trace amounts of water can be absorbed from the environment, e.g., by diffusion of moisture from the air into the topical pharmaceutical composition (e.g., the non-aqueous gel), for example during preparation and/or storage of the topical pharmaceutical composition (e.g., the non-aqueous gel). Nevertheless, one of skill in the art will understand that a “substantially anhydrous” topical pharmaceutical composition is one in which no water is added and in which no water is desired.
  • the non-aqueous gel is anhydrous. In some embodiments, the non-aqueous gel comprises 0.0% water.
  • CR stands for “cream.” Formulations described herein starting with the letters CR are understood as creams.
  • the percentage refers to the amount of a compound of Formula I (preferably Compound 1) in said formulation.
  • the formulation “NA03-2.0%” comprises 2.0% Formula I
  • the formulation “NA03-3%” comprises 3% Compound 1.
  • the formulation “AG20-3.2%” comprises 3.2% Compound 1.
  • the formulation “NA03” comprises 6.3% Compound 1.
  • compositions of the present invention include pharmaceutically acceptable salts of said compounds.
  • pharmaceutically acceptable salt refers to pharmaceutically acceptable organic or inorganic salts of a compound of the present invention, in particular acid addition salts.
  • Exemplary salts include, but are not limited to, salts of physiologically acceptable mineral acids, such as hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid, or salts of organic acids, such as methane-sulfonic acid, -toluenesulfonic acid, lactic acid, malic acid, tartaric acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.
  • physiologically acceptable mineral acids such as hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid
  • organic acids such as methane-sulfonic acid, -toluenesulfonic acid, lactic acid, malic acid, tartaric acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.
  • pharmacologically acceptable salts of the compounds of Formula (I) are alkali metal and alkaline earth metal salts such as, for example, sodium, potassium, lithium, calcium or magnesium salts, ammonium salts or salts of organic bases such as, for example, methylamine, dimethylamine, triethylamine, piperidine, ethylenediamine, lysine, choline hydroxide, meglumine, morpholine or arginine salts.
  • compositions of Formula (I) include the hydrochloride, hydrobromide, sulfate, bisulfate, phosphate, hydrogen phosphate, nitrate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, benzenesulfonate, p- toluenesulphonate or the like.
  • lower mono aliphatic alcohol refers to a saturated organic compound comprising a single hydroxyl group, and further comprising from one to six carbon atoms, wherein said lower mono aliphatic alcohol does not comprise an ether linkage.
  • examples are methanol, ethanol, propanol (e.g., isopropanol), butanol (e.g., isobutanol or tertbutanol), pentanol (e.g., isopentanol), and hexanol (e.g., isohexanol).
  • diethylene glycol monoethyl ether is not considered a lower mono aliphatic alcohol.
  • fatty mono aliphatic alcohol refers to a saturated or mono- or di-unsaturated organic compound comprising a single hydroxyl group, and further comprising at least seven carbon atoms.
  • Preferred fatty mono aliphatic alcohols comprise between 15 and 25 carbon atoms.
  • polyalkylene glycol refers to a polymer having the chemical formula H-[O-CHR-CH2] m -H, wherein “m” represents the average number of repeating oxyethylene groups, and wherein R represents -H or a Ci-Ce alkyl group.
  • Preferred polyalkylene glycols are polyethylene glycol, polypropylene glycol, and polybutylene glycol.
  • PEG refers to a polyethylene glycol, i.e., a polymer having the chemical formula H-[O-CH2-CH2] m -H, wherein “m” represents the average number of repeating oxy ethylene groups.
  • compositions of PEG can typically comprise a range of average molecular weights and can be characterized by an average number of repeating oxy ethylene groups “m.”
  • m average number of repeating oxy ethylene groups
  • Transcutol® P is a registered trademark.
  • Transcutol® P is a trade name referring to di ethylene glycol monoethyl ether, also abbreviated herein as “DEGEE.”
  • the inventive pharmaceutical compositions comprise polyacrylic acid.
  • said polyacrylic acid is crosslinked with allyl sucrose or allyl pentaerythritol.
  • said polyacrylic acid is sold under the trade name “Carbopol®” preferably Carbopol® 974 or Carbopol® 980.
  • the inventive pharmaceutical compositions comprise a polyethylene glycol alkyl ether.
  • said polyethylene glycol alkyl ether is a dialkylene glycol alkyl ether, e.g., a compound of the formula C n H2n+i(OCH2CH2)mOH), wherein “n” is an integer between 1 and 24 and “m” is the average number of repeating oxyethylene units, preferably wherein m is between about 2 and about 20.
  • said polyethylene glycol alkyl ether is sold under the trade name “Brij®.”
  • said polyethylene glycol alkyl ether is Brij® S2, i.e., diethylene glycol-octadecyl ether (Ci8H37(OCH 2 CH 2 ) 2 OH).
  • said polyethylene glycol alkyl ether is Brij® S20, i.e., polyethylene glycol-octadecyl ether (Ci8H37(OCH 2 CH 2 )mOH), wherein m is about 20.
  • GTCC refers to caprylic/capric triglyceride
  • pharmaceutically acceptable excipient includes any physiologically inert additive that is routinely used in pharmaceutical dosage forms.
  • Pharmaceutically acceptable excipients are selected from the group comprising binders, diluents, carriers, lubricants, glidants, coating additives or combinations thereof.
  • solubility synergy factor refers to a measure of the foldincrease in solubility of a compound of Formula (I), e.g., Compound 1, in the inventive topical pharmaceutical compositions over the solubility that would have been expected based on the solubility of the compound of Formula (I) in the individual solvents and excipients alone.
  • hyperkeratosis is understood as the thickening of the stratum comeum.
  • hyperkeratosis is associated with the presence of an abnormal quantity of keratin. Skin that exhibits hyperkeratosis is described herein as “hyperkeratotic”. Skin that does not exhibit hyperkeratosis is described as “non- hyperkeratotic”.
  • hypertrophy is understood to mean the increase in the volume of an organ or tissue due to the enlargement of its component cells.
  • a skin lesion e.g., an actinic keratosis lesion
  • lesions that exhibit hypertrophy are described as being “hypertrophic”.
  • Cells that do not exhibit hypertrophy are described as being “non-hypertrophic”.
  • the present invention provides a topical pharmaceutical composition comprising: at least 0.5 weight percent of a compound of Formula (I): Formula (I) wherein:
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 0.9 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 1.5 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl, or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • the present invention provides a topical pharmaceutical composition comprising: at least 1.9 weight percent of a compound of Formula (I): Formula (I) wherein:
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or Ci-Csalkyl. or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue; at least 30 weight percent, preferably at least 45 weight percent polyalkylene glycol; and at least 10 weight percent, preferably at least 15 weight percent diethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises less than about 5 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 4 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 3 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 2 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 1 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 0.5 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 0.4 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 0.3 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 0.2 weight percent water. In some embodiments, said topical pharmaceutical composition comprises less than about 0.1 weight percent water. In some embodiments, said topical pharmaceutical composition is substantially anhydrous, as defined above.
  • said topical pharmaceutical composition is anhydrous. In some preferred embodiments, said topical pharmaceutical composition comprises 0.0 weight percent water.
  • said topical pharmaceutical composition does not comprise DMSO.
  • said topical pharmaceutical composition comprises less than about 1 weight percent DMSO.
  • said topical pharmaceutical composition comprises less than about 0.9 weight percent DMSO.
  • said topical pharmaceutical composition comprises less than about 0.8 weight percent DMSO.
  • said topical pharmaceutical composition comprises less than about 0.7 weight percent DMSO.
  • said topical pharmaceutical composition comprises less than about 0.6 weight percent DMSO.
  • said topical pharmaceutical composition comprises less than about 1 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.9 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.8 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.7 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.6 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.5 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.4 weight percent lower mono aliphatic alcohol.
  • said topical pharmaceutical composition comprises less than about 0.3 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.2 weight percent lower mono aliphatic alcohol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.1 weight percent lower mono aliphatic alcohol. In some preferred embodiments, said topical pharmaceutical composition does not comprise mono aliphatic alcohol, i.e., said topical pharmaceutical composition comprises 0.0 weight percent lower mono aliphatic alcohol.
  • said topical pharmaceutical composition comprises less than about 1 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.9 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.8 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.7 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.6 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.5 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.4 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.3 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.2 weight percent ethanol. In some embodiments, said topical pharmaceutical composition comprises less than about 0.1 weight percent ethanol. In some embodiments, said topical pharmaceutical composition does not comprise ethanol, i.e., said topical pharmaceutical composition comprises 0.0 weight percent ethanol.
  • said topical pharmaceutical composition comprises polyacrylic acid. In some embodiments, said composition comprises from about 0.1 weight percent to about 10 weight percent polyacrylic acid. In some embodiments, said composition comprises from about 0.5 weight percent to about 5 weight percent polyacrylic acid. In some embodiments, said composition comprises from about 0.5 weight percent to about 2.5 weight percent polyacrylic acid. In some embodiments, said composition comprises from about 0.5 weight percent to about 1.5 weight percent polyacrylic acid.
  • said polyacrylic acid is Carbopol® 974. In some embodiments, said polyacrylic acid is Carbopol® 980.
  • said topical pharmaceutical composition comprises less than about 1 weight percent polyacrylic acid, preferably less than about 0.1 weight percent polyacrylic acid. In some embodiments, said topical pharmaceutical composition does not comprise polyacrylic acid, i.e., said topical pharmaceutical composition comprises 0.0 weight percent polyacrylic acid.
  • the preservative is present from about 0.01% (w/w) to about 5% (w/w), preferably about 0.1% (w/w) to about 5% (w/w), more preferably about 1% (w/w) to about 3% (w/w), based on the total weight of said topical composition.
  • said topical composition comprises one or more other preservative, wherein said preservative is benzyl alcohol, and wherein said benzyl alcohol is present from about 0.01% (w/w) to about 5% (w/w), preferably about 0.1% (w/w) to about 5% (w/w), more preferably about 1% (w/w) to about 3% (w/w) and even more preferably of about 2% (w/w) based on the total weight of said topical composition.
  • said preservative is benzyl alcohol
  • said benzyl alcohol is present from about 0.01% (w/w) to about 5% (w/w), preferably about 0.1% (w/w) to about 5% (w/w), more preferably about 1% (w/w) to about 3% (w/w) and even more preferably of about 2% (w/w) based on the total weight of said topical composition.
  • said topical composition comprises a preservative, wherein said preservative is benzyl alcohol, and wherein said benzyl alcohol is present from about 0.01% (w/w) to about 5% (w/w), preferably about 0.1% (w/w) to about 5% (w/w), more preferably about 1% (w/w) to about 3% (w/w) and even more preferably of about 2% (w/w) based on the total weight of said topical composition.
  • said preservative is benzyl alcohol
  • said benzyl alcohol is present from about 0.01% (w/w) to about 5% (w/w), preferably about 0.1% (w/w) to about 5% (w/w), more preferably about 1% (w/w) to about 3% (w/w) and even more preferably of about 2% (w/w) based on the total weight of said topical composition.
  • said topical pharmaceutical composition does not comprise any preservative, i.e., said topical pharmaceutical composition comprises 0.0 weight percent preservative.
  • said topical composition comprises benzyl alcohol, and wherein said benzyl alcohol is present from about 0.01% (w/w) to about 5% (w/w), preferably about 0.1% (w/w) to about 5% (w/w), more preferably about 1% (w/w) to about 3% (w/w) and even more preferably of about 2% (w/w) based on the total weight of said topical composition.
  • said topical pharmaceutical composition does not comprise benzyl alcohol.
  • said topical pharmaceutical composition comprises a fatty aliphatic alcohol, more preferably wherein said fatty alcohol comprises between 15 and 25 carbon atoms.
  • said fatty alcohol is fully saturated or comprises one or two olefins, more preferably one olefin.
  • said topical composition does not comprise a fatty aliphatic alcohol.
  • said fatty aliphatic alcohol is oleyl alcohol.
  • said oleyl alcohol is present from about 1 weight percent to about 5 weight percent, more preferably from about 1 weight percent to about 4 weight percent, more preferably from about 1 weight percent to about 3 weight percent, more preferably from about 1 weight percent to about 2 weight percent, yet more preferably about 1.5 weight percent.
  • said topical composition does not comprise oleyl alcohol.
  • said topical pharmaceutical composition comprises a thickening agent.
  • Thickening agents are known to the skilled person in the art and includes a cellulose derivative, polyvinylpyrrolidone, a carbomer polymer, a carbomer derivative, maltodextrin, polydextrose, dextrates, carboxypolymethylene, polyvinyl alcohol, poloxamers and mixtures thereof.
  • thickening agents serve to increase the final viscosity of the topical composition, preferably to ensure and increase the time of stay of the topical composition on the skin of a subject, for example, on the site of a skin lesion and/or skin disorder.
  • said thickening agent is selected from the group consisting of carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (“HPC”), sodium hyaluronate and polyvinylpyrrolidone.
  • said thickening agent is carboxymethyl cellulose.
  • said thickening agent is hydroxyethyl cellulose.
  • said thickening agent is hydroxypropyl cellulose.
  • said thickening agent is sodium hyaluronate.
  • said thickening agent is polyvinylpyrrolidone.
  • HPC HF is understood to mean pharmaceutical grade hydroxypropyl cellulose.
  • HPC hydroxypropyl cellulose
  • HF hydroxypropyl cellulose
  • said HPC HF is KlucelTM HCF HF.
  • said composition comprises from about 0.1 weight percent to about 10 weight percent thickening agent. In some embodiments, said composition comprises from about 0.5 weight percent to about 5 weight percent thickening agent. In some embodiments, said composition comprises from about 0.5 weight percent to about 2.5 weight percent thickening agent. In some embodiments, said composition comprises from about 0.5 weight percent to about 1.5 weight percent thickening agent.
  • said composition comprises at least 1 weight percent thickening agent. In some embodiments, said composition comprises at most 1 weight percent thickening agent. In some embodiments, said composition comprises about 1 weight percent thickening agent.
  • said composition comprises from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises from about 0.5 weight percent to about 5 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises from about 0.5 weight percent to about 2.5 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises from about 0.5 weight percent to about 1.5 weight percent hydroxypropyl cellulose.
  • said composition comprises at least 1 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises at most 1 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises about 1 weight percent hydroxypropyl cellulose.
  • said topical pharmaceutical composition comprises from about 0.1 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 0.2 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 0.3 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 0.4 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 0.5 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 0.9 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 1.0 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.5 weight percent to about 8 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.5 weight percent to about 7.9 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 7.5 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 7 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 6.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 1.9 weight percent to about 6 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 5 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 4 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 3 weight percent of a compound Formula (I). In preferred embodiments, said topical pharmaceutical composition comprises from about 1.5 weight percent to about 2.5 weight percent of a compound Formula (I). In preferred embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I). In very preferred embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 2.1 weight percent of a compound Formula (I). In some embodiments, said topical pharmaceutical composition comprises about 2.0 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises at least about 0.1 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 0.2 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 0.3 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 0.4 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 0.5 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 0.9 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 1 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises at least about 1.5 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 1.6 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 1.7 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 1.8 weight percent of a compound of Formula (I). In preferred embodiments, said topical pharmaceutical composition comprises at least about 1.9 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 2.0 weight percent of a compound of Formula (I). In some embodiments, said composition comprises at least about 2.5 weight percent, of a compound of Formula (I).
  • said composition comprises at least about 3.0 weight percent of a compound of Formula (I). In some embodiments, said composition comprises at least about 3.5 weight percent of a compound of Formula (I). In some embodiments, said composition comprises at least about 4.0 weight percent, of a compound of Formula (I). In some embodiments, said composition comprises at least about 4.5 weight percent of a compound of Formula (I). In some embodiments, said composition comprises at least about 5.0 weight percent of a compound of Formula (I). In some embodiments, said composition comprises at least about 5.5 weight percent of a compound of Formula (I). In some embodiments, said composition comprises at least about 6.0 weight percent of a compound of Formula (I).
  • said composition comprises at least about 6.3 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 6.5 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 7.0 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 7.5 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 7.7 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 7.8 weight percent of a compound of Formula (I). In some embodiments, said topical pharmaceutical composition comprises at least about 7.9 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 0.1 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 0.2 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 0.3 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 0.4 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 0.5 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 0.9 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.0 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 1.5 weight percent to about 8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.5 weight percent to about 7.9 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 7.5 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 7 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 6.5 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 6 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 1.9 weight percent to about 4 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 3 weight percent of Compound 1. In preferred embodiments, said topical pharmaceutical composition comprises from about 1.5 weight percent to about 2.5 weight percent of Compound 1. In preferred embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 2.5 weight percent of Compound 1. In very preferred embodiments, said topical pharmaceutical composition comprises from about 1.9 weight percent to about 2.1 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises at least about 0.1 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 0.2 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 0.3 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 0.4 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 0.5 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 0.9 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 1 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 1.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises at least about 1.6 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 1.7 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 1.8 weight percent of Compound 1. In preferred embodiments, said topical pharmaceutical composition comprises at least about 1.9 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 2.0 weight percent of Compound 1. In some embodiments, said composition comprises at least about 2.5 weight percent, of Compound 1. In some embodiments, said composition comprises at least about 3.0 weight percent of Compound 1. In some embodiments, said composition comprises at least about 3.5 weight percent of Compound 1. In some embodiments, said composition comprises at least about 4.0 weight percent, of Compound 1.
  • said composition comprises at least about 4.5 weight percent of Compound 1. In some embodiments, said composition comprises at least about 5.0 weight percent of Compound 1. In some embodiments, said composition comprises at least about 5.5 weight percent of Compound 1. In some embodiments, said composition comprises at least about 6.0 weight percent of Compound 1. In some embodiments, said composition comprises at least about 6.3 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 6.5 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 7.0 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 7.5 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 7.7 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 7.8 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises at least about 7.9 weight percent of Compound 1.
  • said polyalkylene glycol is selected from polyethylene glycol (PEG), polypropylene glycol, and polybutylene glycol and combinations thereof.
  • said polyalkylene glycol is polyethylene glycol.
  • said polyethylene glycol is selected from PEG 200, PEG 300, PEG 400, PEG 540, PEG 600, PEG 900, PEG 1000, PEG 1450, PEG 1540, PEG 2000, PEG 3000, PEG 3350, PEG 4000, PEG 4600, PEG 8000, or a combination thereof.
  • said polyethylene glycol is selected from PEG 200, PEG 300, PEG 400, PEG 540, PEG 600, PEG 900, PEG 1000, or a combination thereof. In some embodiments, said polyethylene glycol is selected from PEG 200, PEG 300, PEG 400, PEG 540, PEG 600, or a combination thereof. In some embodiments, said polyethylene glycol is selected from PEG 300, PEG 400, PEG 540, or a combination thereof. In preferred embodiments, said polyethylene glycol is selected from PEG 400.
  • said topical pharmaceutical composition comprises at least 30 weight percent polyalkylene glycol, preferably polyethylene glycol. In some embodiments, said topical pharmaceutical composition comprises at least 35 weight percent polyalkylene glycol, preferably polyethylene glycol. In some embodiments, said topical pharmaceutical composition comprises at least 40 weight percent polyalkylene glycol, preferably polyethylene glycol. In some embodiments, said topical pharmaceutical composition comprises at least 45 weight percent polyalkylene glycol, preferably polyethylene glycol. In some embodiments, said topical pharmaceutical composition comprises at least 50 weight percent polyalkylene glycol, preferably polyethylene glycol. In some embodiments, said topical pharmaceutical composition comprises at least 55 weight percent polyalkylene glycol, preferably polyethylene glycol. In some embodiments, said topical pharmaceutical composition comprises about 57.81 weight percent polyalkylene glycol, preferably polyethylene glycol.
  • said topical pharmaceutical composition comprises from about 30 weight percent to about 80 weight percent polyalkylene glycol. In some embodiments, said topical pharmaceutical composition comprises from about 35 weight percent to about 80 weight percent polyalkylene glycol. In some embodiments, said topical pharmaceutical composition comprises from about 40 weight percent to about 80 weight percent polyalkylene glycol. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 70 weight percent polyalkylene glycol.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol. In some preferred embodiments, said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol. In some preferred embodiments, said topical pharmaceutical composition comprises from about 53 weight percent to about 60 weight percent polyalkylene glycol. In some preferred embodiments, said topical pharmaceutical composition comprises from about 55 weight percent to about 60 weight percent polyalkylene glycol.
  • said topical pharmaceutical composition comprises at least 45 weight percent PEG 400. In some embodiments, said topical pharmaceutical composition comprises at least 50 weight percent PEG 400. In some embodiments, said topical pharmaceutical composition comprises at least 55 weight percent PEG 400. In some embodiments, said topical pharmaceutical composition comprises about 57.8 weight percent PEG 400.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG 400. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG 400. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 70 weight percent PEG 400. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG 400. In some preferred embodiments, said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG 400. In some preferred embodiments, said topical pharmaceutical composition comprises from about 53 weight percent to about 60 weight percent PEG 400. In some preferred embodiments, said topical pharmaceutical composition comprises from about 55 weight percent to about 60 weight percent PEG 400.
  • said topical pharmaceutical composition comprises from about 10 weight percent to about 35 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises from about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 22 weight percent to about 25 weight percent diethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises at least 10 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises at least 15 weight percent di ethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises at least 19 weight percent diethylene glycol monoethyl ether. In preferred embodiments, said composition comprises at least 20 weight percent diethylene glycol monoethyl ether. In preferred embodiments, said composition comprises at least 21 weight percent di ethylene glycol monoethyl ether. In preferred embodiments, said composition comprises at least 22 weight percent diethylene glycol monoethyl ether. In preferred embodiments, said composition comprises at least 23 weight percent diethylene glycol monoethyl ether. In preferred embodiments, said composition comprises about 24.5 weight percent di ethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises diisopropyl adipate. In some embodiments, said composition comprises from about 1 weight percent to about 20 weight percent diisopropyl adipate. In some embodiments, said composition comprises from about 1 weight percent to about 15 weight percent diisopropyl adipate. In some embodiments, said composition comprises from about 5 weight percent to about 15 weight percent diisopropyl adipate. In some embodiments, said composition comprises from about 7 weight percent to about 13 weight percent diisopropyl adipate. In some embodiments, said composition comprises from about 9 weight percent to about 11 weight percent diisopropyl adipate.
  • said composition comprises at least about 5 weight percent diisopropyl adipate. In some embodiments, said composition comprises at least about 6 weight percent diisopropyl adipate. In some embodiments, said composition comprises at least about 7 weight percent diisopropyl adipate. In some embodiments, said composition comprises at least about 8 weight percent diisopropyl adipate. In some embodiments, said composition comprises at least about 9 weight percent diisopropyl adipate. In some embodiments, said composition comprises at least about 9.3 weight percent diisopropyl adipate. In some embodiments, said composition comprises about 9.36 weight percent diisopropyl adipate. In some embodiments, said composition comprises about 9.8 weight percent diisopropyl adipate.
  • said topical pharmaceutical composition comprises glycerol. In some embodiments, said composition comprises from about 1 weight percent to about 10 weight percent glycerol. In some embodiments, said composition comprises from about 3 weight percent to about 8 weight percent glycerol. In some embodiments, said composition comprises from about 4 weight percent to about 6 weight percent glycerol.
  • said composition comprises at least 3 weight percent glycerol. In some embodiments, said composition comprises at least 4 weight percent glycerol. In some embodiments, said composition comprises at least 4.5 weight percent glycerol. In some embodiments, said composition comprises at least 5 weight percent glycerol. In some embodiments, said composition comprises 3 weight percent glycerol. In preferred embodiments, said composition comprises 4 weight percent glycerol. In some embodiments, said composition comprises 5 weight percent glycerol. In some embodiments, said composition comprises about 4.89 weight percent glycerol.
  • said composition comprises from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises from about 0.5 weight percent to about 5 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises from about 0.5 weight percent to about 2.5 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises from about 0.5 weight percent to about 1.5 weight percent hydroxypropyl cellulose.
  • said composition comprises at least 1 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises at most 1 weight percent hydroxypropyl cellulose. In some embodiments, said composition comprises about 1 weight percent hydroxypropyl cellulose.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol and from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent poly alkylene glycol and from about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol and about 15 weight percent to about 30 weight percent di ethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent poly alkylene glycol and about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol and about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol and about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol and about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400 and from about 15 weight percent to about 35 weight percent di ethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400 and from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400 and about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400 and about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400 and about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400 and about 20 weight percent to about 30 weight percent di ethylene glycol monoethyl ether. In some embodiments, said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG, preferably PEG400 and about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; and from about 0.1 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; and from about 0.5 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; and from about 0.9 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent poly alkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1 weight percent to about 7.9 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 7 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent poly alkylene glycol; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol; about 20 weight percent to about 25 weight percent di ethylene glycol monoethyl ether; and from about 1 .9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; and from about 0. 1 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; and from about 0.5 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; and from about 0.9 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1 weight percent to about 7.9 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 7 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1. In some embodiments, said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG, preferably PEG400; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; and from about 0.1 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; and from about 0.5 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; and from about 0.9 weight percent to about 8 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; and from about 1 weight percent to about 7.9 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 7 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent poly alkylene glycol; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 9 weight percent to about 11 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of a compound Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; and from about 0.1 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; and from about 0.5 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; and from about 0.9 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; and from about 1 weight percent to about 7.9 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 7 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG, preferably PEG400; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 9 weight percent to about 11 weight percent diisopropyl adipate; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 0.1 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 0.5 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 0.9 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 1 weight percent to about 7.9 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 1.9 weight percent to about 7 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; and from about 1.9 weight percent to about 5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 9 weight percent to about 11 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 0.1 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 0.5 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 0.9 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 1 weight percent to about 7.9 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; and from about 1.9 weight percent to about 7 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; and from about 1.9 weight percent to about 5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG, preferably PEG400; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 9 weight percent to about 11 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.1 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.5 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.9 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 1 weight percent to about 7.9 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.5 weight percent to about 5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 7 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 0.5 weight percent to about 5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 0.5 weight percent to about 2.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 0.5 weight percent to about 2.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 0.5 weight percent to about 1.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 9 weight percent to about 11 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 0.5 weight percent to about 1.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of a compound of Formula (I).
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.1 weight percent to about 8 weight percent of Compound 1.
  • PEG preferably PEG400
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.1 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.5 weight percent to about 8 weight percent of Compound 1.
  • PEG preferably PEG400
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.5 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.9 weight percent to about 8 weight percent of Compound 1.
  • PEG preferably PEG400
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 15 weight percent to about 35 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 20 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 0.9 weight percent to about 8 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose; and from about 1 weight percent to about 7.9 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 15 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 0.5 weight percent to about 5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 7 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 0.5 weight percent to about 5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 5 weight percent to about 15 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 0.5 weight percent to about 2.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 19 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 0.5 weight percent to about 2.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 20 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 7 weight percent to about 13 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 0.5 weight percent to about 1.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG, preferably PEG400; about 20 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 9 weight percent to about 11 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 0.5 weight percent to about 1.5 weight percent hydroxypropyl cellulose; and from about 1.9 weight percent to about 2.5 weight percent of Compound 1.
  • said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycokdiethylene glycol monoethyl ether of about 5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether of about 4.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: diethylene glycol monoethyl ether of about 4:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether of about 3.5:1.
  • said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycokdiethylene glycol monoethyl ether of about 3:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether of about 2.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether of about 2.4:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: diethylene glycol monoethyl ether of about 2:1.
  • said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether from about 1 :1 to about 5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycokdiethylene glycol monoethyl ether from about 1.5:1 to about 4.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether from about 2:1 to about 4:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ethe from about 2: 1 to about 3.5: 1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of polyalkylene glycol: di ethylene glycol monoethyl ether from about 2:1 to about 3:1.
  • said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 4.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 4:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 3.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 3:1.
  • said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 2.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether of about 2:1.
  • said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether from about 1: 1 to about 5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether from about 1.5:1 to about 4.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400: di ethylene glycol monoethyl ether from about 2:1 to about 4:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400:diethylene glycol monoethyl ether from about 2:1 to about 3.5:1. In some embodiments, said topical pharmaceutical composition comprises a weight ratio of PEG 400:diethylene glycol monoethyl ether from about 2: 1 to about 3: 1.
  • said composition comprises: at least about 6.0 weight percent of Compound 1; at least about 55 weight percent polyethylene glycol, preferably PEG400; at least about 23 weight percent diethylene glycol monoethyl ether; at least about 4.5 weight percent glycerol; at least about 9 weight percent diisopropyl adipate; and about 1 weight percent hydroxypropyl cellulose.
  • said composition comprises less than 1% water, preferably less than 0.1% water.
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% water, preferably less than 0.1% water. In preferred embodiments, said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises: at least about 2.0 weight percent of Compound 1; at least about 55 weight percent polyethylene glycol, preferably PEG400; at least about 23 weight percent diethylene glycol monoethyl ether; at least about 4.5 weight percent glycerol; at least about 9 weight percent diisopropyl adipate; and about 1 weight percent hydroxypropyl cellulose.
  • said composition comprises less than 1% water, preferably less than 0.1% water.
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% water, preferably less than 0.1% water. In preferred embodiments, said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol. In preferred embodiments, said composition does not comprise DMSO.
  • said composition comprises: from about 1.5 weight percent to about 2.5 weight percent, preferably from about 1.9 weight percent to about 2.5 weight percent Compound 1; from about 45 weight percent to about 75 weight percent polyethylene glycol, preferably PEG400; from about 15 weight percent to about 30 weight percent di ethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent glycerol; from about 5 weight percent to about 15 weight percent diisopropyl adipate; and from about 0.1 weight percent to about 10 weight percent hydroxypropyl cellulose.
  • the present disclosure provides a topical aqueous pharmaceutical composition.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 20 weight percent water; and from about 0.1 weight percent, preferably about 0.5 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent polyalkylene glycol; from about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 20 weight percent water; and from about 0.9 weight percent to about 8 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 20 weight percent water; and from about 1 weight percent to about 7.9 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 7 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 2 weight percent to about 8 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 1 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 5 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent polyalkylene glycol; about 15 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 2 weight percent to about 8 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 5 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 4 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 15 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 2 weight percent to about 9 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 5 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 4 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent polyalkylene glycol; about 15 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 3 weight percent to about 6 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 9 weight percent to about 11 weight percent water; and from about 1.9 weight percent to about 4 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent polyalkylene glycol; about 18 weight percent to about 22 weight percent diethylene glycol monoethyl ether; from about 3 weight percent to about 6 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 9 weight percent to about 11 weight percent water; and from about 1.9 weight percent to about 4 weight percent of a compound of Formula (I).
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 10 weight percent to about 30 weight percent di ethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 20 weight percent water; and from about 0.1 weight percent, preferably about 0.5 weight percent, to about 8 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 80 weight percent PEG, preferably PEG400; from about 10 weight percent to about 30 weight percent di ethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 20 weight percent water; and from about 0.9 weight percent to about 8 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 20 weight percent water; and from about 1 weight percent to about 7.9 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 1 weight percent to about 10 weight percent diisopropyl adipate; from about 1 weight percent to about 10 weight percent glycerol; from about 1 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 7 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 10 weight percent to about 30 weight percent diethylene glycol monoethyl ether; from about 2 weight percent to about 8 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 1 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 5 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 75 weight percent PEG, preferably PEG400; about 15 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 2 weight percent to about 8 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 5 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 4 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 15 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 2 weight percent to about 9 weight percent diisopropyl adipate; from about 3 weight percent to about 8 weight percent glycerol; from about 5 weight percent to about 15 weight percent water; and from about 1.9 weight percent to about 4 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 45 weight percent to about 65 weight percent PEG, preferably PEG400; about 15 weight percent to about 25 weight percent diethylene glycol monoethyl ether; from about 3 weight percent to about 6 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 9 weight percent to about 11 weight percent water; and from about 1.9 weight percent to about 4 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises from about 50 weight percent to about 60 weight percent PEG, preferably PEG400; about 18 weight percent to about 22 weight percent diethylene glycol monoethyl ether; from about 3 weight percent to about 6 weight percent diisopropyl adipate; from about 4 weight percent to about 6 weight percent glycerol; from about 9 weight percent to about 11 weight percent water; and from about 1.9 weight percent to about 4 weight percent of Compound 1.
  • said topical aqueous pharmaceutical composition comprises at least about 3 weight percent of Compound 1; at least about 9 weight percent water; at least about 54 weight percent polyethylene glycol, preferably PEG400; at least about 19 weight percent di ethylene glycol monoethyl ether; at least about 4 weight percent glycerol; at least about 4 weight percent diisopropyl adipate; at least about 2 weight percent benzyl alcohol; and about 1 weight percent polyacrylic acid.
  • said composition comprises less than about 1% ethanol, preferably less than about 0.1% ethanol.
  • said topical aqueous pharmaceutical composition comprises 3.2 weight percent of Compound 1; 9.64 weight percent water;
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said topical aqueous pharmaceutical composition comprises at least about 3 weight percent of Compound 1 ; at least about 9 weight percent water; at least about 57 weight percent polyethylene glycol, preferably PEG400; at least about 21 weight percent diethylene glycol monoethyl ether; about 3 weight percent glycerol; about 1.5 weight percent oleyl alcohol; about 2 weight percent benzyl alcohol; and about 1 weight percent polyacrylic acid.
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said topical aqueous pharmaceutical composition comprises
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • polyethylene glycol preferably PEG400
  • polyethylene glycol preferably PEG400
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • polyethylene glycol preferably PEG400
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • polyethylene glycol preferably PEG400
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • polyethylene glycol preferably PEG400
  • polyethylene glycol preferably PEG400
  • said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol.
  • said composition comprises:
  • said composition comprises less than 1% water, preferably less than 0.1% water. In preferred embodiments, said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol. In preferred embodiments, said composition does not comprise DMSO.
  • said composition comprises:
  • glycerol preferably anhydrous glycerol
  • said composition comprises less than 1% water, preferably less than 0.1% water. In preferred embodiments, said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol. In preferred embodiments, said composition does not comprise DMSO. In some embodiments, said composition comprises:
  • glycerol preferably anhydrous glycerol
  • said composition comprises less than 1% water, preferably less than 0.1% water. In preferred embodiments, said composition comprises less than 1% ethanol, preferably less than 0.1% ethanol. In preferred embodiments, said composition does not comprise DMSO.
  • said topical pharmaceutical composition further comprises one or more additional excipients and wherein said pharmaceutically acceptable excipient is selected from the group consisting of a thickening agent, a stabilizer, an antioxidant, a chelating agent, an oily material, an emulsifier, a penetration enhancer, a pH adjusting agent, a preservative, an antimicrobial agent, an opacifier, a fragrance, a colorant, a gelling agent, a moisturizer, a surfactant, and a combination thereof.
  • a pharmaceutically acceptable excipient is selected from the group consisting of a thickening agent, a stabilizer, an antioxidant, a chelating agent, an oily material, an emulsifier, a penetration enhancer, a pH adjusting agent, a preservative, an antimicrobial agent, an opacifier, a fragrance, a colorant, a gelling agent, a moisturizer, a surfactant, and a combination thereof.
  • said topical composition comprises one or more other pharmaceutically acceptable excipients, and said pharmaceutically acceptable excipient is selected from the group consisting of a thickening agent, a stabilizer, an antioxidant, a pH adjusting agent, a preservative, an antimicrobial agent, and a combination thereof.
  • the pharmaceutically acceptable excipients used in the topical composition of the present invention can act in more than one way.
  • a thickening agent can also function as a gelling agent.
  • said topical composition comprises one or more other pharmaceutically acceptable excipients, and one of said pharmaceutically acceptable excipients is a thickening agent. In a preferred embodiment, said topical composition comprises a thickening agent.
  • said topical composition comprises one or more other pharmaceutically acceptable excipients, and one of said pharmaceutically acceptable excipients is an antioxidant. In a preferred embodiment, said topical composition comprises an antioxidant.
  • Antioxidants are known to the skilled person in the art and includes, for example, butylated hydroxyanisole, butylated hydroxytoluene, vitamin C, vitamin E, vitamin A, lutein, lycopene, retinyl palmitate, potassium metabisulfite, sodium metabisulfite, sodium thiosulfate pentahydrate, 3,4-dihydroxybenzoic acid, propyl gallate, alpha-lipoic acid, ascorbyl palmitate, sodium pyrosulfite, ubiquinone, selenium, or a combination thereof.
  • said topical composition comprises one or more excipient, wherein said excipient is an antioxidant selected from butylated hydroxyanisole, butylated hydroxytoluene, vitamin C, vitamin E, vitamin A, lutein, lycopene, retinyl palmitate, potassium metabisulfite, sodium metabisulfite, sodium thiosulfate pentahydrate, 3,4- dihydroxybenzoic acid, propyl gallate, alpha-lipoic acid, ascorbyl palmitate, sodium pyrosulfite, ubiquinone, selenium, or a combination thereof.
  • an antioxidant selected from butylated hydroxyanisole, butylated hydroxytoluene, vitamin C, vitamin E, vitamin A, lutein, lycopene, retinyl palmitate, potassium metabisulfite, sodium metabisulfite, sodium thiosulfate pentahydrate, 3,4- dihydroxybenzoic acid, propyl gallate, alpha-
  • the antioxidant is present from about 0.001% (w/w) to about 0.1% (w/w), preferably about 0.001% (w/w) to about 0.01% (w/w), more preferably about 0.002% (w/w) to about 0.008% (w/w), based on the total weight of said topical composition.
  • said topical pharmaceutical composition further comprises a buffer, preferably a phosphate buffer.
  • said topical composition comprises a buffer, preferably a phosphate buffer, of a pH of about 6.5 to about 7.5, further preferably a buffer, preferably a phosphate buffer, of a pH of about 6.5 to about 7.0, even more preferably a buffer, preferably a buffer, of a pH of about 6.7.
  • said topical composition is in the form of a non-aqueous gel, and wherein said topical composition comprises a phosphate buffer, wherein preferably said topical composition comprises a phosphate buffer of a pH of about 6.5 to about 7.5, further preferably a phosphate buffer of a pH of about 6.5 to about 7.0, even more preferably a phosphate buffer of a pH of about 6.7.
  • said topical composition is in the form of an aqueous gel, and wherein said topical composition comprises an aqueous phosphate buffer, wherein preferably said topical composition comprises an aqueous phosphate buffer of a pH of about 6.5 to about 7.5, further preferably an aqueous phosphate buffer of a pH of about 6.5 to about 7.0, even more preferably an aqueous phosphate buffer of a pH of about 6.7.
  • said buffer preferably said phosphate buffer, has a molarity of about 10 to about 15 mM, preferably of about 12mM.
  • said buffer is a phosphate buffer, wherein said phosphate buffer has a molarity of about 10 to about 15 mM, preferably of about 12mM.
  • inventive pharmaceutical compositions comprise a compound of
  • W is H or F
  • Y is N or CH
  • R 1 and R 2 are independently of each other a morpholinyl of Formula (II) Formula (II) wherein R 3 and R 4 are independently of each other H or -Ci-Csalkyl; or R 3 and R 4 combine to form a bivalent Ci-Csalkylene residue.
  • R 1 and R 2 are each independently of each other selected from: In some embodiments, R 1 and R 2 are each independently of each other selected from:
  • the compound of Formula (I) is selected from: 5-(4,6-dimorpholino-l,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (Compound 1); 4-(difluoromethyl)-5-(4,6-dimorpholino-l,3,5-triazin-2-yl)pyrimidin-2-amine (Compound 2);
  • the compound of Formula (I) is 5-(4,6-dimorpholino-l,3,5- triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (Compound 1), also known as “PQR309” and “bimiralisib”:
  • the compound of Formula (I) is 4-(difhioromethyl)-5-(4,6- dimorpholino-l,3,5-triazin-2-yl)pyrimidin-2-amine (Compound 2):
  • the compound of Formula (I) is 5-(4-(3-oxa-8- azabicyclo[3.2.1]octan-8-yl)-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-l,3,5-triazin-2-yl)-4- (difluoromethyl)pyridin-2-amine (Compound 3):
  • the compound of Formula (I) is (S)-4-(difluoromethyl)-5-(4-(3- methylmorpholino)-6-morpholino-l,3,5-triazin-2-yl)pyridin-2-amine (Compound 4): In some embodiments, the compound of Formula (I) is 4-(difluoromethyl)-5-[4-
  • topical pharmaceutical composition for use in treatment of a disease shall disclose also the corresponding method of treatment and the corresponding use of a preparation for the manufacture of a medicament for the treatment of a disease.
  • the present invention provides the inventive topical pharmaceutical compositions for use as a medicament.
  • inventive topical pharmaceutical compositions were safe and effective for the treatment of skin lesions such as actinic keratosis as demonstrated by a randomized phase 2 clinical trial.
  • the safety profile of the inventive topical pharmaceutical compositions suggested that they were well-tolerated, with related adverse events being mostly grade 1 in nature.
  • Related adverse events such as lesion erosion, crusting and erythema resolved rapidly after the end of treatment.
  • the four-week treatment period was not observed to add significant additional toxicity over the 2-week treatment. Only one patient out of a group of 42 patients treated stopped treatment before the full course was completed.
  • inventive topical pharmaceutical compositions showed high levels of efficacy with 60% of patients exhibiting lesions that were either completely or partially cleared at the 4- week follow-up visit (70% in Arm B and 50% in Arm A of the phase 2 trial).
  • the present invention provides the inventive topical pharmaceutical compositions for use in the prevention or treatment of a skin lesion or skin disorder in a subj ect, wherein said inventive topical pharmaceutical compositions are administered topically to said subject.
  • said inventive topical pharmaceutical composition is administered to said subject once daily. In some embodiments, said inventive topical composition is administered once daily for two weeks or four weeks. In some embodiments, said inventive topical composition is administered once daily for two weeks. In some embodiments, said inventive topical composition is administered once daily for four weeks.
  • the present invention provides the inventive topical pharmaceutical compositions for use in the prevention or treatment of a skin lesion or skin disorder in a subject, wherein said inventive topical pharmaceutical composition is administered once daily.
  • the present invention provides the inventive topical pharmaceutical compositions for use in the prevention or treatment of actinic keratosis in a subject, wherein said inventive topical pharmaceutical composition is administered once daily.
  • the present invention provides the inventive topical pharmaceutical compositions for use in the prevention or treatment of cutaneous squamous cell carcinoma in a subject, wherein said inventive topical pharmaceutical composition is administered once daily.
  • the present invention provides a method of treating a skin lesion or skin disorder in a subject in need thereof, the method comprising topically administering to said subject an inventive topical pharmaceutical composition of the disclosure, preferably wherein said topical pharmaceutical composition is administered once daily.
  • the present invention provides the use of an inventive topical pharmaceutical composition of the disclosure in the manufacture of a medicament for topical treatment of a skin lesion or skin disorder in a subject, preferably wherein said topical pharmaceutical composition is for once daily administration.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a skin lesion in a subject, wherein said topical pharmaceutical composition comprising a compound of Formula (I) is administered topically, preferably once daily, to the subject.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a skin lesion in a subject, preferably wherein said skin lesion is nonmelanoma skin cancer (NMSC), a cutaneous lymphoma or a pre-invasive form thereof.
  • NMSC nonmelanoma skin cancer
  • said skin lesion is a pre-invasive form of non-melanoma skin cancer (NMSC).
  • NMSC non-melanoma skin cancer
  • said skin lesion is a nonmelanoma skin cancer (NMSC).
  • NMSC nonmelanoma skin cancer
  • said skin lesion is a cutaneous lymphoma.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a non-melanoma skin cancer (NMSC) in a subject, wherein said non-melanoma skin cancer is a cutaneous squamous cell carcinoma (cSCC) or a basal cell carcinoma.
  • NMSC non-melanoma skin cancer
  • cSCC cutaneous squamous cell carcinoma
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a cutaneous squamous cell carcinoma (cSCC) in a subject.
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a cutaneous squamous cell carcinoma (cSCC) in a subject.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a cutaneous squamous cell carcinoma (cSCC) in a subject, wherein said cutaneous squamous cell carcinoma (cSCC) is an invasive cSCC.
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a cutaneous squamous cell carcinoma (cSCC) in a subject, wherein said cutaneous squamous cell carcinoma (cSCC) is an invasive cSCC.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a cutaneous squamous cell carcinoma (cSCC) in a subject, wherein said cutaneous squamous cell carcinoma (cSCC) is a metastatic cSCC.
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a cutaneous squamous cell carcinoma (cSCC) in a subject, wherein said cutaneous squamous cell carcinoma (cSCC) is a metastatic cSCC.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a basal cell carcinoma in a subject.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is selected from the group consisting of superficial basal cell carcinoma (also known as “in situ basal cell carcinoma” or “superficial multicentric basal-cell carcinoma”), infiltrative basal cell carcinoma and nodular basal cell carcinoma.
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is selected from the group consisting of superficial basal cell carcinoma (also known as “in situ basal cell carcinoma” or “superficial multicentric basal-cell carcinoma”), infiltrative basal cell carcinoma and nodular basal cell carcinoma.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is a superficial basal cell carcinoma (also known as “in situ basal cell carcinoma” or “superficial multicentric basal-cell carcinoma”).
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is a superficial basal cell carcinoma (also known as “in situ basal cell carcinoma” or “superficial multicentric basal-cell carcinoma”).
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is an infiltrative basal cell carcinoma.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is a nodular basal cell carcinoma.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a basal cell carcinoma in a subject, wherein said basal cell carcinoma is selected from the group consisting of cystic basal cell carcinoma, cicatricial basal cell carcinoma (also known as “morpheaform basal cell carcinoma” or “morphoeic basal cell carcinoma”), micronodular basal cell carcinoma, pigmented basal cell carcinoma, rodent ulcer (also known as “Jacob’s ulcer”), fibroepithelioma of Pinkus, polypoid basal cell carcinoma, pore-like basal cell carcinoma and aberrant basal cell carcinoma.
  • cystic basal cell carcinoma cicatricial basal cell carcinoma
  • micronodular basal cell carcinoma pigmented basal cell carcinoma
  • rodent ulcer also known as “Jacob’s ulcer”
  • fibroepithelioma of Pinkus polypoid basal cell carcinoma
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a pre-invasive form of non-melanoma skin cancer (NMSC) in a subject, wherein said pre-invasive form is selected from the group consisting of cutaneous squamous cell carcinoma in situ (cSCCis, also known as “Bowen’s disease”), precancerous actinic keratosis (AK) and chronic UV damage.
  • cSCCis cutaneous squamous cell carcinoma in situ
  • AK precancerous actinic keratosis
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a pre-invasive form of non-melanoma skin cancer (NMSC), wherein said pre-invasive form is cutaneous squamous cell carcinoma in situ (cSCCis, also known as “Bowen’s disease”).
  • NMSC non-melanoma skin cancer
  • cSCCis cutaneous squamous cell carcinoma in situ
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a pre-invasive form of non-melanoma skin cancer (NMSC) in a subject, wherein said pre-invasive form is precancerous actinic keratosis (AK).
  • NMSC non-melanoma skin cancer
  • AK precancerous actinic keratosis
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a pre-invasive form of non-melanoma skin cancer (NMSC) in a subject, wherein said pre-invasive form is chronic UV damage.
  • NMSC non-melanoma skin cancer
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of actinic keratosis (AK), e.g., precancerous actinic keratosis (AK) in a subject, wherein said AK is a field cancerization.
  • AK actinic keratosis
  • AK precancerous actinic keratosis
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of actinic keratosis (AK), preferably wherein said actinic keratosis comprises at least 3 actinic keratosis lesions, preferably wherein said at least 3 actinic keratosis lesions are of Olsen grade 1 or 2.
  • said at least 3 actinic keratosis lesions are non-hypertrophic.
  • said at least 3 actinic keratosis lesions are non-hyperkeratotic.
  • said at least 3 actinic keratosis lesions are contained within contiguous treatment regions, preferably up to a total area of about 100 cm 2 , more preferably wherein said at least 3 actinic keratosis lesions are on the face, scalp, and/or the back of the hands of a subject.
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of actinic keratosis (AK), wherein said actinic keratosis comprises at least 3 actinic keratosis lesions of Olsen grade 1 or 2, wherein said actinic keratosis lesions are non-hypertrophic and non-hyperkeratotic and contained within contiguous treatment regions up to a total area of about 100 cm 2 on the face, scalp, and/or the back of the hands of a subject.
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of actinic keratosis (AK), wherein said actinic keratosis comprises at least 3 actinic keratosis lesions of Olsen grade 1 or 2, wherein said actinic keratosis lesions are non-hypertrophic and non-hyperkeratotic and contained within con
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a cutaneous lymphoma in a subject, wherein said cutaneous lymphoma is a cutaneous T-cell lymphoma (CTCL) or a cutaneous B-cell lymphoma (CBCL).
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a cutaneous lymphoma in a subject, wherein said cutaneous lymphoma is a cutaneous T-cell lymphoma (CTCL) or a cutaneous B-cell lymphoma (CBCL).
  • CTCL cutaneous T-cell lymphoma
  • CBCL cutaneous B-cell lymphoma
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a cutaneous T-cell lymphoma (CTCL) in a subject.
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a cutaneous T-cell lymphoma (CTCL) in a subject.
  • CTCL cutaneous T-cell lymphoma
  • a topical pharmaceutical composition comprising a compound of Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a cutaneous lymphoma in a subject, wherein said cutaneous lymphoma is a cutaneous B-cell lymphoma (CBCL).
  • a compound of Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a cutaneous lymphoma in a subject, wherein said cutaneous lymphoma is a cutaneous B-cell lymphoma (CBCL).
  • CBCL cutaneous B-cell lymphoma
  • a topical pharmaceutical composition comprising a compound Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a skin disorder in a subject.
  • a skin disorder is a genodermatosis.
  • said genodermatosis is selected from tuberous sclerosis complex (TSC), Birt-Hogg-Dube (BHD, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome, and hereditary keratinopathy, wherein preferably said genodermatosis is selected from a skin disorder associated with tuberous sclerosis complex (TSC), a skin disorder associated with Birt-Hogg-Dube (BHD, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome, and hereditary keratinopathy.
  • TSC tuberous sclerosis complex
  • BHD Birt-Hogg-Dube
  • PTEN phosphatase and tensin homolog
  • said genodermatosis is tuberous sclerosis complex (TSC). In a further preferred embodiment, said genodermatosis is tuberous sclerosis complex minus (TSC-). In a further preferred embodiment, said genodermatosis is Birt-Hogg-Dube (BHD or also named hereditary fibroma). In a further preferred embodiment, said genodermatosis is phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS). In a further preferred embodiment, said genodermatosis is hereditary keratinopathy.
  • TSC tuberous sclerosis complex
  • TSC- tuberous sclerosis complex minus
  • BHD Birt-Hogg-Dube
  • PTEN tensin homolog
  • PHTS hamartoma tumor syndrome
  • said genodermatosis is hereditary keratinopathy.
  • said genodermatosis is hereditary keratinopathy, wherein said hereditary keratinopathy is pachyonychia congenita.
  • said genodermatosis is a skin disorder associated with tuberous sclerosis complex (TSC).
  • said genodermatosis is a skin disorder associated with Birt- Hogg-Dube (BHD).
  • said skin disorder associated with tuberous sclerosis complex is an angiofibroma (AF).
  • said skin disorder associated with tuberous sclerosis complex is a facial angiofibroma.
  • said skin disorder associated with tuberous sclerosis complex is a hamartoma.
  • said skin disorder associated with tuberous sclerosis complex is a periungual fibroma.
  • said skin disorder associated with Birt-Hogg-Dube are fibrofolliculomas of BHD.
  • said skin disorder is hereditary keratinopathy.
  • said skin disorder is pachyonychia congenita.
  • said PTEN hamartoma tumor syndrome is selected from Cowden syndrome (CS), Bannayan- Riley-Ruvalcaba syndrome (BRRS), PTEN- related Proteus syndrome (PS), Lhermitte-Duclos syndrome and Proteus-like syndrome.
  • said PTEN hamartoma tumor syndrome (PHTS) is Cowden syndrome (CS).
  • said PTEN hamartoma tumor syndrome (PHTS) is Bannayan-Riley-Ruvalcaba syndrome (BRRS).
  • said PTEN hamartoma tumor syndrome (PHTS) is PTEN-related Proteus syndrome (PS).
  • said PTEN hamartoma tumor syndrome is Lhermitte- Duclos syndrome.
  • said PTEN hamartoma tumor syndrome is Proteus-like syndrome.
  • said hereditary keratinopathy wherein preferably said hereditary keratinopathy is pachyonychia congenita.
  • said skin disorder is PTEN hamartoma tumor syndrome (PHTS), wherein preferably said PTEN hamartoma tumor syndrome (PHTS) is selected from Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN- related Proteus syndrome (PS), Lhermitte-Duclos syndrome and Proteus-like syndrome.
  • said skin disorder is Cowden syndrome (CS).
  • said skin disorder is Bannayan-Riley-Ruvalcaba syndrome (BRRS).
  • said skin disorder is PTEN-related Proteus syndrome (PS).
  • said skin disorder is Lhermitte-Duclos syndrome. In a further preferred embodiment, said skin disorder is Proteus-like syndrome. In a further preferred embodiment, said skin disorder is skin fibrosis. In a further preferred embodiment, said skin disorder is hamartoma. In a further preferred embodiment, said skin disorder is periungual fibroma.
  • said skin disorder is a genodermatosis, wherein said genodermatosis is selected from tuberous sclerosis complex (TSC), Birt-Hogg-Dube (BHD, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS), and hereditary keratinopathy.
  • TSC tuberous sclerosis complex
  • BHD Birt-Hogg-Dube
  • PTEN phosphatase and tensin homolog
  • PHTS hamartoma tumor syndrome
  • hereditary keratinopathy hereditary keratinopathy
  • said skin disorder is a vascular anomaly, wherein said vascular anomaly is selected from port- wine stain (PWS), infantile hemangioma, blue rubber bleb nevus syndrome and a complex vascular anomaly.
  • PWS port- wine stain
  • infantile hemangioma infantile hemangioma
  • blue rubber bleb nevus syndrome and a complex vascular anomaly.
  • said skin disorder is a vascular anomaly.
  • said vascular anomaly is selected from port-wine stain (PWS), infantile hemangioma, blue rubber bleb nevus syndrome and a complex vascular anomaly.
  • said vascular anomaly is port- wine stain (PWS or also named as Sturge Weber syndrome).
  • said vascular anomaly is infantile hemangioma.
  • said vascular anomaly is blue rubber bleb nevus syndrome.
  • said vascular anomaly is a complex vascular anomaly.
  • said vascular anomaly is a complex vascular anomaly, wherein said complex vascular anomaly is kaposiform hemangioendothelioma.
  • said skin disorder is selected from port-wine stain (PWS), infantile hemangioma, blue rubber bleb nevus syndrome and a complex vascular anomaly.
  • said skin disorder is port-wine stain (PWS or also named as Sturge Weber syndrome).
  • said skin disorder is infantile hemangioma.
  • said skin disorder is blue rubber bleb nevus syndrome.
  • said skin disorder is a complex vascular anomaly.
  • said skin disorder is a complex vascular anomaly, wherein said complex vascular anomaly is kaposiform hemangioendothelioma.
  • said skin disorder is kaposiform hemangioendothelioma.
  • said skin disorder is selected from scleroderma, sclerodermatous chronic graft- versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars, preferably hypertrophic scars.
  • said skin disorder is scleroderma. In a further preferred embodiment, said skin disorder is sclerodermatous chronic graft-versus-host disease. In a further preferred embodiment, said skin disorder is lichen sclerosus. In a further preferred embodiment, said skin disorder is lichen planus. In a further preferred embodiment, said skin disorder is lichen ruber planus. In a further preferred embodiment, said skin disorder is a scar. In a further preferred embodiment, said skin disorder is a hypertrophic scar.
  • said skin disorder is selected from a skin disorder associated with tuberous sclerosis complex (TSC) or Birt-Hogg-Dube (BHD, an angiofibroma (AF), preferably a facial angiofibroma, fibrofolliculoma of BHD, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS), Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), Lhermitte-Duclos syndrome, Proteus-like syndrome, hereditary keratinopathy, pachyonychia congenita, vascular anomaly, skin fibrosis, hamartoma, periungual fibroma, a vascular anomaly, port- wine stain (PWS), infantile hemangioma, blue rubber bleb nevus syndrome, a complex vascular anomaly, kaposiform heman
  • TSC tuberous
  • said skin disorder is an angiofibroma (AF). In a further very preferred embodiment, said skin disorder is a facial angiofibroma.
  • AF angiofibroma
  • a topical pharmaceutical composition comprising a compound Formula (I) according to the invention (preferably Compound 1 ) for use in the prevention or treatment of a skin disorder in a subject wherein said skin disorder is a genodermatosis, wherein said genodermatosis is selected from tuberous sclerosis complex (TSC), Birt-Hogg-Dube (BHD, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS), and hereditary keratinopathy, wherein said compound of Formula (I) is administered topically to the subject.
  • TSC tuberous sclerosis complex
  • BHD Birt-Hogg-Dube
  • PTEN phosphatase and tensin homolog
  • PHTS hamartoma tumor syndrome
  • hereditary keratinopathy wherein said compound of Formula (I) is administered topically to the subject.
  • a topical pharmaceutical composition comprising a compound Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a skin disorder in a subject, wherein said skin disorder is a vascular anomaly, wherein said vascular anomaly is selected from port- wine stain (PWS), infantile hemangioma, blue rubber bleb nevus syndrome and a complex vascular anomaly, and wherein said topical pharmaceutical composition is administered topically to the subject.
  • a compound Formula (I) according to the invention preferably Compound 1
  • said topical pharmaceutical composition is administered topically to the subject.
  • a topical pharmaceutical composition comprising a compound Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a skin disorder in a subject, wherein said skin disorder is selected from a skin disorder associated with tuberous sclerosis complex (TSC) or Birt-Hogg-Dube (BHD, an angiofibroma (AF), preferably a facial angiofibroma, fibrofolliculoma of BHD, phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS), Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), Lhermitte-Duclos syndrome, Proteus-like syndrome, hereditary keratinopathy, pachyonychia congenita, vascular anomaly, skin fibrosis, hamartoma, periungual fibroma, a vascular anomal
  • TSC tuberous sclerosis
  • a topical pharmaceutical composition comprising a compound Formula (I) according to the invention (preferably Compound 1) for use in the prevention or treatment of a skin disorder in a subject, wherein said skin disorder is an angiofibroma (AF), preferably a facial angiofibroma, wherein said topical pharmaceutical composition is administered topically to the subject.
  • a compound Formula (I) according to the invention preferably Compound 1 for use in the prevention or treatment of a skin disorder in a subject, wherein said skin disorder is an angiofibroma (AF), preferably a facial angiofibroma
  • AF angiofibroma
  • said topical pharmaceutical composition is administered topically to the subject.
  • the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 1.1. In some embodiments, the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 1.5. In some embodiments, the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 2.0. In some embodiments, the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 2.5. In some embodiments, the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 3.0. In some embodiments, the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 3.5.
  • the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 4.0. In some embodiments, the inventive topical pharmaceutical compositions have a solubility synergy factor of at least 4.5. In some embodiments, the inventive topical pharmaceutical compositions provide a clinically relevant concentration of a compound of Formula (I) to the skin of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of a compound of Formula (I) is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of a compound of Formula (I) is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of a compound of Formula (I) is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of a compound of Formula (I) is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of a compound of Formula (I) to the dermis and/or epidermis of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of a compound of Formula (I) in the dermis and/or epidermis of said patient is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of a compound of Formula (I) is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of a compound of Formula (I) in the dermis and/or epidermis of said patient is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of a compound of Formula (I) is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of a compound of Formula (I) to the dermis of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of a compound of Formula (I) in the dermis of said patient is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of a compound of Formula (I) is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of a compound of Formula (I) in the dermis of said patient is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of a compound of Formula (I) is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of a compound of Formula (I) to the epidermis of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of a compound of Formula (I) in the epidermis of said patient is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of a compound of Formula (I) is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of a compound of Formula (I) in the epidermis of said patient is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of a compound of Formula (I) is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of Compound 1 to the skin of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of Compound 1 is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of Compound 1 is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of Compound 1 is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of Compound 1 is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of Compound 1 to the dermis and/or epidermis of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of Compound 1 in the dermis and/or epidermis of said patient is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of Compound 1 is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of Compound 1 in the dermis and/or epidermis of said patient is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of Compound 1 is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of Compound 1 to the dermis of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of Compound 1 in the dermis of said patient is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of Compound 1 is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of Compound 1 in the dermis of said patient is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of Compound 1 is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the inventive topical pharmaceutical compositions provide a clinically relevant concentration of Compound 1 to the epidermis of a patient, preferably after a single application to said patient.
  • said clinically relevant concentration of Compound 1 in the epidermis of said patient is above the clinical IC90 for inhibition of pAKT, e.g., said clinically relevant concentration of Compound 1 is above 1,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • said clinically relevant concentration of Compound 1 in the epidermis of said patient is above the clinical IC90 for inhibition of pS6, e.g., said clinically relevant concentration of Compound 1 is above 3,000 ng/g, preferably wherein said concentration is reached after a single application of the inventive topical pharmaceutical composition.
  • the concentration of Compound 1 in the formulations described in Table 1 represents the upper limit (i. e. , 80-90%) of the total solubility of Compound 1 in those formulations.
  • Compound 1 was first tested for solubility in various individual solvents and excipients. Table 2 below gives the solubility of Compound 1 in individual solvents and excipients at 25 °C, measured in weight/weight ratios. For example, for PEG400, 1.66% wt/wt solubility means that 1.66 g Compound 1 were soluble in 100 g PEG400.
  • Table 3 shows the solubility synergy factors observed for the formulations NA03, AG20, and CR01.
  • the amount of Compound 1 added represented 80% of the total amount of Compound 1 possible to dissolve in the formulation.
  • An in vitro drug release test was performed using a static Franz cell as shown in FIG 1 to assess the release profile of Compound 1 across a synthetic cellulose membrane from the ten experimental formulations AG02, AG11, AG12, AG15, AG18, AG20, AG21, NA03, EG01, and CR01. Briefly, a formulation comprising Compound 1 was placed above a synthetic cellulose membrane and allowed to diffuse over time through the membrane and into a receiver fluid which did not initially contain Compound 1 as shown in FIG 1.
  • receiver fluids were initially tested to confirm the stability of Compound 1 in the receiver fluid.
  • the receiver fluid selected for use was of 2% Brij® in 50/50 ethanol/water.
  • Compound 1 was found to be stable over five days in the selected receiver fluid at 5, 25, and 32 °C.
  • a cellulose membrane was selected for use because it did not allow any back diffusion when used with the receiver fluid and did not bind to Compound 1.
  • the Franz cell had a dosing area of 1.9 to 2.4 cm 2 and a volume of 7.5-11 mL.
  • FIG 2 and Table 5 show the amount of Compound 1 released across the synthetic cellulose membrane and into the receptor solution over seven hours.
  • the non-aqueous gel (NA03) showed the fastest release rate of Compound 1 (P ⁇ 0.0001 for all formulations), which ranged from approximately 2-5 -fold increase compared to all other formulations.
  • the release rate of the ten tested formulations ranged from 216-1084 pg/cm 2 /hr, with the slowest release rate of Compound 1 observed in CR01 and AG18.
  • the cumulative amount of Compound 1 in the receiver fluid seven hours after dosing escalated with the percent of Compound 1 present in the applied formulation.
  • the formulations AG20, EG01, and AG21 all had statistically the same release rates and were the next-highest ranked formulations for release rate after NA03.
  • EXAMPLE 4 EX VIVO HUMAN SKIN PERMEATION AND PENETRATION
  • the ex vivo skin permeation experiments involve the use of a diffusion cell designed to mimic the physiological and anatomical conditions of skin in situ.
  • a schematic of the model used to test skin permeation in this Example is shown in FIG 3. Human skin was placed between the donor and receptor compartments.
  • a flow path with small void volumes provided local clearance beneath the dermatomed skin to generate accurate and detailed flux profiles through automated collection and optimized fluidics.
  • a receiver solution of PBS with 0.01% Brij® was used based on non-specific binding experiments and the high stability of Compound 1 in the receiver solution.
  • Formulation AG11 was used to test the experimental conditions. Cumulative levels of approximately 100 ng/cm 2 Compound 1 were detected in the receptor solution after 24 hours, and Compound 1 was recovered from the epidermis and dermis. Based on these results, the conditions were deemed suitable for a full-scale ex vivo skin permeation and penetration study.
  • the recovery of the residual formulation on the skin for the full-scale experiment was performed as follows: A total of three cotton swabs were used to recover the drug (Compound 1) from the surface of the skin. After removing the skin from the diffusion cell, one dry cotton wool swab was used to remove all of the formulation from the surface of the skin and the swab was discarded. A second swab was then immersed into the extraction solution and used to swab the surface of the skin. The swab was then discarded. The final swab was used to dry swab the surface of the skin and then discarded.
  • Compound 1 was removed from the stratum corneum using the following procedure: Tape strips (5 strips) were removed from the surface of the skin to separate the stratum corneum from the epidermis and were discarded. The remaining epidermis and partial dermis were heat-separated from each other by placing the skin into an incubator at 60 °C for 2 min. The epidermal and dermal layers were placed into individual tissue homogenizer vials and 1 mL of extraction solution was added. The tissue homogenizer vials were placed in a bead mill homogenizer and the contents were homogenized at 5 m/s for 3 x 30 seconds at ambient laboratory temperature. The vials were then shaken on an orbital shaker at ambient temperature for 0.5-1 h. The homogenate was then transferred to a 96-well plate, which was then centrifuged. The dermis and epidermis samples were analyzed using LC-MS/MS.
  • Formulation NA03 delivered 1.7 to 17-fold more Compound 1 to the epidermis compared with all other tested formulations.
  • Formulation NA03 was also the third -highest ranked formulation for dermal delivery.
  • Formulations AG20 and AG21 delivered the highest amount of Compound 1 to both the dermis and epidermis of the tested aqueous gels.
  • the PK profiles of ten experimental formulations and one control formulation were determined in an in vivo pig skin study using biopsy extraction. Prior to biopsy extraction, the stratum comeum was removed with tape stripping. Three replicate biopsies were taken from each application site (20 x 40 mm). Additionally, three biopsies were taken from a non-treated tape-stripped site (blank samples) for analytical validation. All biopsies were stored at -80 °C until they were analyzed. The formulations tested were AG08, AG11, AG13, AG15, AG17, AG20, AG21, NA03, EG01, and CR01. The control formulation comprised 1% Compound 1 , PG and thickener.
  • a four-month old domestic pig with a weight of 40 kg was used. Three days before the study, the back and both flanks of the pig were shaved. On the day of the study, the pig was anesthetized. The skin was cleaned with water and inspected for wounds, abrasions, or other alterations. The application sites were marked on the skin with a stencil and a surgical marker. A schematic of the application sites is shown in FIG 5.
  • the applied dose for each formulation was 56 mg (7mg/cm 2 of formulation on application area of 4 x 2 cm).
  • the dose was weighed using an analytical balance and applied with a plastic spatula. Dosing was done sequentially. Exposure times were 6, 9 and 12 hours.
  • the pig Upon completion of the exposure times, the pig was euthanized by dosing a premedication of 10 mg/kg ketamine, 0.2 mg/kg midazolam, and 2 mg/kg azaperone and an overdose of propofol and potassium chloride.
  • the remaining formulations Prior to tape stripping, the remaining formulations were removed from the application sites by cleaning the application sites twice with gauze. To remove the stratum comeum, a piece of tape was attached to the skin at all relevant application sites. The tape was uniformly pressed to the skin surface using gloved fingers to ensure homogenous contact of the tape to the skin surface and was abruptly removed with one smooth motion. To completely remove the SC, tape stripping was repeated 80 times using a fresh piece of tape each time and alternating the peeling direction (from left to right and from right to left).
  • biopsies Three replicate biopsies were taken with a biopsy punch (4.0 mm) from each application site. Subcutaneous tissue was removed from the biopsies. The biopsies were placed in 1.8 mL cryotubes and weighed. Additionally, three blank biopsies were taken from untreated and tape-stripped sites to determine the background in the analytical runs. The samples were stored in a temperature-monitored freezer at -80 °C until sample shipment.
  • the concentrations of Compound 1 in all ten formulations and the control formulation were quantifiable in all tissue samples using LC-MS/MS. Mean concentrations, standard deviations (SD) and coefficient of variance (CV) were calculated for each formulation and point in time. The resulting CVs were between 6% and 89%.
  • FIG 6 shows the concentration of Compound 1 in pig skin biopsies at each time point tested.
  • FIG 7 shows the amount of Compound 1 in biopsies integrated over the three time points tested (6, 9 and 12 hours).
  • the dotted line represents the IC90 of Compound 1 on phosphoS6, and the dashed line represents the IC90 of Compound 1 on phosphoAKT.
  • Formulations NA03 and AG20 gave the highest concentrations of Compound 1 in the skin of the experimental compounds tested. As shown in FIG 7, when integrated over the three timepoints tested, formulations NA03 and AG20 delivered an amount of Compound 1 above the IC90 for phosphoS6 inhibition.
  • the formulations were applied at different doses of 1.0 mg/cm 2 , 2.0 mg/cm 2 , 3.5 mg/cm 2 , and 7.0 mg/cm 2 .
  • the application area was 12 cm 2 (4 cm x 3 cm).
  • a 2.5 -month old domestic pig (weight: 33 kg) was delivered to the study site.
  • Four days before the study start the application areas on the back and both flanks of the pig were shaved with a hair clipper.
  • the pig was anesthetized and the skin was cleaned with water and inspected for wounds, abrasions, and other alterations.
  • the application sites were marked on the skin with a surgical stencil and surgical marker.
  • test formulations containing Compound 1 were applied on ten application sites for an exposure time of 6 hours; on ten application sites for an exposure time of 9 hours; and on a further ten application sites for an exposure time of 12 hours.
  • placebo formulations i. e. , formulations NA03 and AG20 not containing Compound 1
  • the location of application of the formulations to the pig is shown in FIG 8.
  • the formulations were applied with a plastic spatula.
  • the pig was euthanized.
  • the remaining experimental formulations were removed from the application sites by cleaning the application sites twice with gauze.
  • the stratum comeum was removed by tape stripping.
  • Tape was applied to the skin on the application sites. The tape was uniformly pressed to the skin surface with gloved fingers to provide homogenous contact of the tape to the skin surface and was then immediately removed in one smooth motion.
  • tape stripping was repeated 80 times by using a fresh piece of tape each time and by alternating peeling direction (from left to right and right to left). The tape stripping procedure took approximately 70 minutes for all sites.
  • Biopsies consisted of the remaining epidermis and the entire dermis. From the application sites treated with formulations containing Compound 1 , six replicate biopsies were taken with a biopsy punch (4.0 mm), three of which were tested for pharmacokinetic profiling. From the two application sites treated with placebo cream, three biopsies were taken. Additionally, three blank biopsies from a non-treated tape-stripped site were taken to determine the background in the analytical runs. The biopsies were placed in 1.8 mL cryo tubes and weighed. All biopsy samples were stored at -80 °C until analysis.
  • Table 9 shows the Compound 1 concentrations in the skin for each formulation tested.
  • FIG 9 shows the averaged (mean ⁇ SEM) Compound 1 concentrations of all formulations over all time points (6h, 9h, 12 h).
  • the dotted line represents the IC90 of Compound 1 on phosphoS6, and the dashed line represents the IC90 of Compound 1 on phosphoAKT.
  • EXAMPLE 7 A RANDOMIZED PHASE 2 PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOPICAL BIMIRALISIB APPLICATION IN PATIENTS SUFFERING FROM ACTINIC KERATOSIS ON THE FACE AND/OR SCALP AND/OR BACK OF HANDS OVER A 2 AND 4-WEEK TREATMENT PERIOD
  • Cosmetic or therapeutic procedures e.g. laser, peeling, photodynamic therapy, cryotherapy
  • Cosmetic or therapeutic procedures within 4 weeks of the Baseline visit and within 2 cm of the selected treatment area.
  • HIV human immunodeficiency virus
  • chronic hepatitis C chronic hepatitis C
  • chronic hepatitis B infection testing not mandatory
  • polyethylene glycol preferably PEG400; 24.50 weight percent di ethylene glycol monoethyl ether;
  • the target lesion on-treatment response were measured as the change from baseline for (i) Investigator Global Assessment (IGA), (ii) absolute lesion count, and (iii) lesion size.
  • IGA Investigator Global Assessment
  • IGA success were defined as achieving an IGA score of 0 or 1 at the follow-up visit.
  • Absolute lesion count was characterized by “Complete clearance”: absence of clinically visible or palpable AK lesions in the treatment area; “Partial clearance”: at least 75% reduction in the number of AK lesions in the treatment area.
  • Lesion size was calculated by measuring perpendicular dimensions and calculated area for each of the selected target lesions, and as the sum total value of area of all selected target lesions.
  • Secondary outcomes include safety, tolerability, and the percentage of partial clearance of AK lesions.
  • AK lesions Twenty-nine (29) patients were initially enrolled. No treatment interruptions occurred. Administration of the topical formulation led to significant reductions in AK lesions: 50% (Arm A) and 58% (Arm B) achieved an IGA score of 0-1, respectively.
  • Topical bimiralisib gel (2%) thus demonstrated efficacy in the treatment of AK, with a favorable safety profile.
  • Adverse events were based on the initial treatment period (2- or 4- weeks) and safety follow-up of 28 days.
  • Table 10 summarizes all adverse events for the 42 patients treated at the time of patient evaluation.
  • Table 11 summarizes the treatment-related adverse events.
  • Table 12 gives the details of treatment-related adverse events.
  • Efficacy Table 13 is a summary of the efficacy results that were observed in the 35 patients that had reached the primary endpoint at the time of patient evaluation based on the Investigator Global Assessment compared to the baseline.
  • the formulations above were prepared by transferring pre-weighed PEG400, Transcutol P®, diisopropyl adipate, and glycerol into a glass laboratory vessel. The mixture was stirred at a suitable speed to create a flow throughout the vessel until the solution was visually homogenous. Pre-weighed Compound 1 was transferred into the vessel while stirring at a speed to create a flow throughout the vessel. The mixture was stirred until the Compound 1 was dissolved. Pre-weighed hydroxypropyl cellulose was transferred into the vessel while stirring at a speed suitable to create a sufficient vortex. The stirring was continued at a suitable speed to create a flow throughout the vessel until the hydroxypropyl cellulose had completely dissolved.
  • Non-aqueous gel formulations NA03-2% and NA03-6.3% were tested for stability based on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) stability testing standards for up to 24 months. All procedures were performed according to current EU GMP guidelines for Investigational Medicinal Products (IMPs) as defined in the “EudraLex - Volume 4 Good manufacturing practice (GMP) Guidelines”. QC testing was conducted based on the principles of European Directives 2001/20/EC, 2003/94/EC, and EudraLex cGMP guidelines.
  • Stability samples were stored in stability testing chambers for the duration of the study and were removed from the stability testing chambers at designated time points for analysis as specified below.
  • a single vessel containing NA03-2% was used to fill each test sample tube related to NA03-2%, and a single vessel containing NA03-6.3% was used to fill each test sample tube related to NA03-6.3%.
  • Table 19 Summary of stability storage conditions, time points and testing based on a 15 g fill weight.
  • X Full testing performed (macroscopic appearance, microscopic appearance, API assay and related substances, apparent viscosity) — from 3 tubes
  • M Modified quantitative testing (MQT) testing — from 2 tubes.
  • TAMC Total Aerobic Microbial Count
  • TYMC Total Combined Yeast/Moulds Count Table 23, Stability Testing Results for NA03-6,3%.
  • TYMC Total Combined Yeast/Moulds Count

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions topiques comprenant des composés de formule (I) tels que définis dans la description. L'invention concerne également des utilisations desdites compositions topiques pour le traitement de maladies ou de troubles soulagés par l'inhibition de PI3K et/ou mTOR chez un sujet, de préférence chez un être humain, et en particulier, pour le traitement de lésions cutanées et/ou de troubles cutanés.
PCT/EP2025/055580 2024-03-01 2025-02-28 Formulations topiques d'inhibiteurs de pi3k/mtor doubles Pending WO2025181366A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP24160831 2024-03-01
EP24160831.4 2024-03-01
EP24199587.7 2024-09-10
EP24199587 2024-09-10
EP25155314 2025-01-31
EP25155314.5 2025-01-31

Publications (1)

Publication Number Publication Date
WO2025181366A1 true WO2025181366A1 (fr) 2025-09-04

Family

ID=94871445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/055580 Pending WO2025181366A1 (fr) 2024-03-01 2025-02-28 Formulations topiques d'inhibiteurs de pi3k/mtor doubles

Country Status (1)

Country Link
WO (1) WO2025181366A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052569A2 (fr) * 2008-11-10 2010-05-14 University Of Basel Analogues de triazine, pyrimidine et pyridine et leur utilisation en tant qu'agents thérapeutiques et sondes de diagnostic
WO2017198347A1 (fr) 2016-05-18 2017-11-23 Piqur Therapeutics Ag Traitement de lésions cutanées
WO2019087158A2 (fr) 2017-11-06 2019-05-09 Novartis Ag Formulation comprenant un dérivé d'oxazolidine-2-one-pyrimidine
US20220107328A1 (en) * 2018-08-14 2022-04-07 Camp4 Therapeutics Corporation Methods of treating liver diseases
EP4306524A2 (fr) * 2017-08-29 2024-01-17 PureTech LYT, Inc. Promédicaments lipidiques dirigeant le système lymphatique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052569A2 (fr) * 2008-11-10 2010-05-14 University Of Basel Analogues de triazine, pyrimidine et pyridine et leur utilisation en tant qu'agents thérapeutiques et sondes de diagnostic
WO2017198347A1 (fr) 2016-05-18 2017-11-23 Piqur Therapeutics Ag Traitement de lésions cutanées
EP4306524A2 (fr) * 2017-08-29 2024-01-17 PureTech LYT, Inc. Promédicaments lipidiques dirigeant le système lymphatique
WO2019087158A2 (fr) 2017-11-06 2019-05-09 Novartis Ag Formulation comprenant un dérivé d'oxazolidine-2-one-pyrimidine
US20220107328A1 (en) * 2018-08-14 2022-04-07 Camp4 Therapeutics Corporation Methods of treating liver diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. L. FOGEL ET AL., J. AM. ACAD. DERMATOL, vol. 72, 2015, pages 879 - 89
AYLI EE ET AL., J. CUTANEOUS PATHOLOGY, vol. 35, 2008, pages 273 - 277
HA EUN-SOL ET AL: "Application of diethylene glycol monoethyl ether in solubilization of poorly water-soluble drugs", JOURNAL OF PHARMACEUTICAL INVESTIGATION, SPRINGER SINGAPORE, SINGAPORE, vol. 50, no. 3, 7 June 2019 (2019-06-07), pages 231 - 250, XP037107730, ISSN: 2093-5552, [retrieved on 20190607], DOI: 10.1007/S40005-019-00454-Y *
R. C. ROWEP. J. SHESKEYM. E. QUINN: "Handbook of Pharmaceutical Excipients", 2009, PHARMACEUTICAL PRESS
SAXTON RASABATINI DM, CELL, vol. 168, 2017, pages 960 - 976

Similar Documents

Publication Publication Date Title
JP5345937B2 (ja) 抗真菌組成物
EP3273940B1 (fr) Composition de tétracycline pharmaceutique pour usage dermatologique
EP2691077B1 (fr) Preparation topique contenant de l'acide salicylique
AU2019213835A1 (en) Topical formulations comprising tofacitinib
ES2797376T3 (es) Composiciones para la administración transdérmica de inhibidores de mTOR
JP6796638B2 (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
US20050137164A1 (en) Diclofenac compositions for the treatment of skin disorders
EP3439632B1 (fr) Composition topique comprenant du tacrolimus
US20180344640A1 (en) Econazole composition and methods of treatment therewith
EP4426297A1 (fr) Utilisations de pan-inhibiteurs de bet
WO2025181366A1 (fr) Formulations topiques d'inhibiteurs de pi3k/mtor doubles
TW202002977A (zh) 治療搔癢症的組合物與方法
KR20240134863A (ko) 심부 진피 약물 전달을 위한 스피로노락톤의 약학 조성물
CN116887813A (zh) 水凝胶组合物及其在预防和/或治疗由辐射引起的皮肤损伤中的用途
US20250000869A1 (en) Topical compositions of 2-phenyl-3, 4-dihydropyrrolo [2, l-f] [1, 2, 4] triazinone derivatives and uses thereof
US20130324502A1 (en) Novel formulations for dermal, transdermal and mucosal use 1
EP4382104A1 (fr) Dyclonine pour le traitement topique du syndrome main-pied
TW202519237A (zh) 用於治療痤瘡樣疹之皮甾酮-17α-丙酸酯
IL322781A (en) Combination treatment with calcitriol and minoxidil
EP4529925A1 (fr) Cortexolone-17-alpha-propionate pour le traitement des éruptions acneiformes
CN118414154A (zh) 泛bet抑制剂的用途
HK1249032B (en) Pharmaceutical tetracycline composition for dermatological use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25710012

Country of ref document: EP

Kind code of ref document: A1